Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-30T17:08:14.275Z Has data issue: false hasContentIssue false
  • English
  • Français

Commentary: Risks and Benefits, Testing and Screening, Cancer, Genes and Dollars

Published online by Cambridge University Press:  01 January 2021

Eric Kodish
Get access Rights & Permissions [Opens in a new window]

Extract

The ability to determine genetic predisposition to cancer represents an opportunity to expand cancer control efforts in a manner that was previously unimaginable. This possibility also forces individual patients, families, health care professionals, and society to confront difficult questions about genetic knowledge. Although genetic testing or screening for cancer risk may hold promise of cancer control benefits, this prospect also raises significant ethical and legal concerns that must inform and shape policy decisions. In “Cancer Genetic Susceptibility Testing,” Benjamin Wilfond and the Cancer Genetic Screening Consortium (CGSC) present a status report and an ambitious agenda for future examination of ethical and policy issues in this embryonic field. The paper provides a provocative and timely discussion of some extremely vexing issues, but it also misses on several critical points.

Type
Article
Information
Journal of Law, Medicine & Ethics , Volume 25 , Issue 4 , Winter 1997 , pp. 252 - 255
Copyright
Copyright © American Society of Law, Medicine and Ethics 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

See Kahn, P., “Coming to Grips with Genes and Risk,” Science, 274 (1996): 496–98.CrossRefGoogle Scholar
See Wilfond, B., “Cancer Genetic Susceptibility Testing: Ethical and Policy Implications for Future Research and Clinical Practice,” Journal of Law, Medicine & Ethics, 25 (1997): 243–51.CrossRefGoogle Scholar
See Task Force on Genetic Information and Insurance, National Center for Human Genome Research, Genetic Information and Health Insurance (Bethesda: National Institutes of Health, 1993).Google Scholar
See Wilfond, , supra note 2, at 248.Google Scholar
See Hoskins, K.F., “Assessment and Counseling for Women with a Family History of Breast Cancer,” JAMA, 273 (1995): 577–85.CrossRefGoogle Scholar
See Biesecker, B.B. Boehnke, M. Calzone, K., “Genetic Counseling for Families with Inherited Susceptibility to Breast and Ovarian Cancer,” JAMA, 269 (1993): 1970–74.CrossRefGoogle Scholar
See Wilfond, , supra note 2, at 243.Google Scholar
See Rimer, B.K. Schildkraut, J., “Cancer Screening,” in DeVita, V.T. Hellman, S. Rosenberg, S.A., eds., Cancer: Principles and Practice of Oncology (Philadelphia: Lippincott-Raven, 5th ed., 1997): Ch. 25.Google Scholar
See Motulsky, A.G., “Screening for Genetic Diseases,” N. Engl. J. Med., 336 (1997): 1314–16.CrossRefGoogle Scholar
See Rimer, Schildkraut, , supra note 8, at 619.Google Scholar
See Kramer, B.S., “The Screening Editorial Board of the Physician Data Query: NCI State of the Art Statements on Cancer Screening” in Greenwall, P. Kramer, B.S. Weed, D.L., eds., Cancer Prevention and Control (New York: Marcel Dekker, 1995): 719–22.Google Scholar
See, for example, Collins, F.S., “Statement on the Use of DNA Testing for Presymptomatic Identification of Cancer Risk,” JAMA, 271 (1994): 785; and American Society of Clinical Oncology, “Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility,” Journal of Clinical Oncology, 14 (1996): 1730–36.CrossRefGoogle Scholar
See Schulman, J.D. Stern, H.J., “Genetic Predisposition Testing for Breast Cancer” (visited Feb. 18, 1998) <http://www.givf.com/cancer_Journal1.html> (reprint from The Cancer Journal (1996)).+(reprint+from+The+Cancer+Journal+(1996)).>Google Scholar
See Myriad Genetics, A Corporate Commitment to Responsible Genetic Testing (visited Oct. 14, 1996) <http://www.myriad.com/Commitment>..>Google Scholar
Id. at 1.Google Scholar
See Hubbard, R. Lewontin, R.C., “Pitfalls of Genetic Testing,” N. Engl. J. Med., 334 (1996): 1192–94.CrossRefGoogle Scholar
For example, Myriad Genetics, OncorMed, and Genetics IVF Institute.Google Scholar
See Rosenberg, S.A., “Secrecy in Medical Research,” N. Engl. J. Med., 334 (1996): 392–94.CrossRefGoogle Scholar
See Kodish, E. Whitehouse, P. Murray, T., “Conflict of Interest in University-Industry Research Relationships: Realities, Politics and Values,” Academic Medicine, 71 (1996): 7–10.CrossRefGoogle Scholar
See Fletcher, S.W., “Whither Scientific Deliberation in Health Policy Recommendations?,” N. Engl. J. Med., 336 (1997):1180–83.CrossRefGoogle Scholar
See Chodak, G., “Prostate Cancer: To Screen or Not to Screen,” Acta Oncologica, 30 (1991): 285–87.CrossRefGoogle Scholar
See Kodish, E., “Genetic Testing for Cancer Risk: How to Reconcile the Conflict,” JAMA, 279 (1998): 179–81.CrossRefGoogle Scholar